Monoclonal Antibodies Which Specifically Bind to the Ligand Hepatocyte Growth Factor (HGF) and are Useful in the Treatment of Ca
Posted Feb 28 2006 4:00pm
Description of Invention: The invention described and claimed in this patent application provides for compositions and methods for the treatment of cancers associated with hepatocyte growth factor (HGF). In particular, the patent application describes compositions and methods which employ a combination of monoclonal antibodies which bind to HGF and prevent it from binding to its receptor met in a manner that HGF/met signaling is neutralized. The combination of monoclonal antibodies has been shown to be neutralizing in tumor-bearing nude mice.
HGF/met signaling has been most widely studied in settings related to cancer. It has been demonstrated to have a role in metastasis and angiogenesis. In addition to cancer, HGF activity has also been linked, through its role in apoptosis, to Alzheimer’s disease and cardiovascular disease.
The application has been published as WO 01/34650 (05/17/2001). The work has also been published at Cao B, et al PNAS USA 98(13):7443-8 (June 19 2001) [ http://www.pnas.org/cgi/content/full/98/13/7443 ]. The hybridomas which can be used to produce the various monoclonal antibodies have been deposited with the ATCC and are available to licensees. Only U.S. Patent protection has been sought for this technology. There are no foreign counterpart patent applications.
Licensing Status: This application is available for license only. Licenses for the development of therapeutics may be exclusive or non-exclusive. The principal investigators are no longer at the NIH and are not available for NIH collaborative projects under the CRADA mechanism.
Portfolios: Cancer Cancer - Therapeutics Cancer - Research Materials Internal Medicine Internal Medicine - Therapeutics Central Nervous System Central Nervous System - Therapeutics
For Additional Information Please Contact: Susan Rucker J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 30A, Rockville, MD 20852 United States Email: ruckersu@mail.nih.gov Phone: 301-435-4478 Fax: 301-402-0220
Description of Invention:
The invention described and claimed in this patent application provides for compositions and methods for the treatment of cancers associated with hepatocyte growth factor (HGF). In particular, the patent application describes compositions and methods which employ a combination of monoclonal antibodies which bind to HGF and prevent it from binding to its receptor met in a manner that HGF/met signaling is neutralized. The combination of monoclonal antibodies has been shown to be neutralizing in tumor-bearing nude mice.
HGF/met signaling has been most widely studied in settings related to cancer. It has been demonstrated to have a role in metastasis and angiogenesis. In addition to cancer, HGF activity has also been linked, through its role in apoptosis, to Alzheimer’s disease and cardiovascular disease.
The application has been published as WO 01/34650 (05/17/2001). The work has also been published at Cao B, et al PNAS USA 98(13):7443-8 (June 19 2001) [ http://www.pnas.org/cgi/content/full/98/13/7443 ]. The hybridomas which can be used to produce the various monoclonal antibodies have been deposited with the ATCC and are available to licensees. Only U.S. Patent protection has been sought for this technology. There are no foreign counterpart patent applications.
Inventors:
Boliang Cao
Patent Status:
HHS, Reference No. E-262-1999/1
US, , Patent No. 7,459,536, Issued 02 Dec 2008
HHS, Reference No. E-262-1999/1
Licensing Status:
This application is available for license only. Licenses for the development of therapeutics may be exclusive or non-exclusive. The principal investigators are no longer at the NIH and are not available for NIH collaborative projects under the CRADA mechanism.
Portfolios:
Cancer
Cancer - Therapeutics
Cancer - Research Materials
Internal Medicine
Internal Medicine - Therapeutics
Central Nervous System
Central Nervous System - Therapeutics
For Additional Information Please Contact:
Susan Rucker J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 30A,
Rockville, MD 20852
United States
Email: ruckersu@mail.nih.gov
Phone: 301-435-4478
Fax: 301-402-0220
Ref No: 1317
Updated: 03/2006